Adjuvant transfusion of donor lymphocytes (aDLT) may reduce the risk of relapse after allogeneic stem cell transplantation in high-risk AML. We performed a retrospective analysis on the safety and efficacy of aDLT in a cohort of 46 patients. To be eligible for aDLT, patients had to be in CR for at least 120 days from transplantation, off immunosuppression for ⩾ 30 days and free of GvHD. Thirty-four patients with similar disease characteristics and fulfilling the same selection criteria served as controls. Median follow-up among aDLT recipients was 7.2 years. Ten patients (22%) relapsed inspite of aDLT, as compared with 53% in the control group. Induction of GvHD was the main complication. However, non-relapse mortality was low with patients dying from infection (n = 2), severe chronic GvHD (n = 1) and secondary malignancy (n = 2). At the time of analysis, 31/46 aDLT recipients were alive in CR at a median of 5.7 years after first aDLT. Overall survival at 7 years after transplant was 67% as compared with 31% in the control group (P o 0.001). In conclusion, aDLT is safe, when given in escalating doses to a well predefined group of patients. Long-term survival can be achieved. 
INTRODUCTION
Despite advances in allogeneic transplantation (allogeneic stem cell transplantation; alloSCT), high-risk AML remains a disease with poor outcome, lacking optimal therapeutic strategy. In particular, patients with refractory disease or early relapse still have a poor prognosis. High-risk disease can further be defined by delayed response to chemotherapy, unfavorable karyotype or molecular genetics 1 and by a history of preceding neoplasia and/or chemotherapy.
In the era of reduced intensity conditioning (RIC), high rates and a poor outcome of relapse after alloSCT (2 years overall survival (OS) 20%) 2, 3 are the main causes for treatment failure in high-risk AML. Thus, effective strategies for preventing post-transplant relapse are urgently needed. As donor lymphocyte transfusion (DLT) enhances the graft-versus-leukemia (GVL) effect, it offers an attractive therapeutic option to decrease relapse-related mortality rates. The GVL potential of donor T-lymphocytes has been described in several preclinical 4, 5 and clinical studies. [6] [7] [8] In particular, their use in the management of post-transplant relapses of chronic myeloid leukemia has been a story of success. However, despite of its desirable GVL effects, DLT may also increase the incidence and severity of GvHD. Thus, DLT protocols have to be optimized to minimize the risk of severe GvHD and maximize the benefit of the GVL effect.
The establishment of RIC provided a basis for the employment of DLT in the post-transplantation period of AML therapy. There are several clinical studies supporting the positive role of DLT in the prophylaxis 9 and treatment of post-transplant relapse in AML. 2, 10 Despite these encouraging data, the efficacy and the toxicity of DLT in the management of AML is still poorly assessed, and published data from larger cohorts with long-term follow-up are lacking.
11,12
Here, we present a clinical study on adjuvant DLT (aDLT) in a cohort of 46 high-risk AML patients following FLAMSA-RIC alloSCT from related and unrelated donors in two German transplant centers. We retrospectively analyzed the toxicity and efficacy of aDLT. In addition, we compared the results with a well-matched control group of 34 patients with similar disease and treatment characteristics.
PATIENTS AND METHODS Patients
Patients were treated within the prospective FLAMSA-RIC study for highrisk AML and myelodysplastic syndrome as defined by cytogenetic aberrations and/or stage of the disease at transplant. 9 For the current analysis, cytogenetics were reclassified according to the European LeukemiaNet criteria. 1 The protocol contained a sequence of chemotherapy (Fludarabin 30 mg/m 2 , Amsacrine 100 mg/m 2 , Cytarabine 2000 mg/m 2 each given for 4 consecutive days), RIC for allogeneic transplantation (either 400 cGray TBI or IV Busulfan 6.4 mg/kg body weight (BW), followed by Cyclophosphamide 80-120 mg/kg BW and ATG-Fresenius 30-60 mg/kg BW, with the higher doses applied in unrelated transplantations) and planned aDLT. Cyclosporin A (targeted plasma trough level 150-200 ng/ml) and mycophenolate mofetil (15 mg/kg bid) were used for GvHD prophylaxis. In the absence of GvHD, cyclosporin A was tapered from days +60 to +90 and mycophenolate mofetil was discontinued by day +45.
As in the initial prospective trial, 9 after adopting the FLAMSA-RIC protocol into routine clinical practice, for aDLT, patients had to meet the following criteria: being in CR for at least 120 days from transplantation, being off immunosuppression for at least 30 days, being free of GvHD and without history of acute GvHD 4II (aGvHD; World Health Organization) and having no severe infection. The median initial dose was 1 × 10 6 CD3+ cells/kg BW in sibling transplants and 5 × 10 5 CD3+ cells/kg BW in the unrelated setting. In the absence of GvHD, aDLT was repeated upto three times, using escalating cell doses (five-to 10-fold increase/transfusion) at 4-to 6-week intervals.
The study was performed according to the modified Declaration of Helsinki Principles and written informed consent including data analysis was obtained from each patient prior to transplantation.
Control group
For a control group, consecutive patients fulfilling the criteria for both, high-risk AML and for aDLT (being alive in CR at day +120, no chronic GvHD (cGvHD) and no history of aGvHD 4II°) and who were transplanted during the same time period, were selected from centers not using aDLT. Of these, the majority received TBI-or Busulfan-based standard conditioning. Stem cell source was bone marrow in eleven patients and mobilized PBSC in the remaining. Standard GvHD prophylaxis with cyclosporin A and methotrexate or mycophenolate mofetil was applied.
Evaluation and statistics
Data were evaluated retrospectively as of 1 June 2012. The two groups were compared with respect to OS, leukemia-free survival (LFS) and relapse incidence. The analysis includes adverse events attributable to aDLT and non-relapse mortality after aDLT. OS was defined as the interval from the date of transplantation to the date of death or last follow-up. LFS was calculated from date of transplantation until relapse or death in CR. Survival analysis was performed using Kaplan-Meier estimates. Differences between the groups were compared by log-rank test. In addition, landmark analyses were performed calculating the survival from the date of first aDLT. The median time from transplant to first aDLT was used as the landmark for calculating survival in the control cohort. Descriptive statistics were performed applying χ 2 or Fisher's exact tests were appropriate. P-values o0.05 were considered significant. Statistical analyses were performed using IBM-SPSS software, version 19, New York, NY, USA.
RESULTS

Patients
From April 1999 to December 2005, 46 patients with high-risk AML received an alloSCT following the FLAMSA-RIC protocol and subsequently aDLT in two German transplant centers (Wiesbaden, n = 12; Munich, n = 34). This number of patients accounted for 30% of all high-risk patients treated within this protocol. Reasons for not giving aDLT included early relapse, active GvHD with continuous need of immunosuppression or a history of severe aGvHD, severe infections or patients' choice.
Thirteen patients of the control group were transplanted in Hannover during the whole time period and 21 patients at the transplant center in Wiesbaden between 2000 and 2002 prior to the introduction of the FLAMSA-RIC protocol in this center.
Patients' characteristics and disease status at transplantation of both groups are summarized in Table 1 . aDLT patients had been transplanted for untreated secondary AML or refractory anemia with excess of blasts (n = 2), primarily refractory (n = 10) or relapsed leukemia (n = 22) or in first CR (CR1) because of unfavorable cytogenetics (n = 7) or other unfavorable criteria (n = 3) or in second CR (CR2) with unfavorable cytogenetics (n = 2). Overall, 25 patients had an unfavorable karyotype (European LeukemiaNet intermediate II and adverse), 10 with complex aberrations. Control group patients had been transplanted for untreated secondary AML or refractory anemia with excess of blasts (n = 5), refractory (n = 9) or relapsed leukemia (n = 12), or in CR1 because of unfavorable cytogenetics (n = 7) or in CR2 with unfavorable cytogenetics (n = 1). Overall, 18 patients had an unfavorable karyotype.
aDLT patients and controls were well matched with respect to age, gender, donor-type, diagnosis and disease status at transplantation and European LeukemiaNet risk stratification. However, bone marrow-derived grafts as compared with G-CSFmobilized PBSC were used more frequently in the control group. In addition, in the control group, a remarkable higher portion of patients received standard myeloablative conditioning and less patients received in vivo T-cell depletion (Table 1) .
DLT characteristics Five patients received DLT in a preemptive setting because of declining or incomplete chimerism (n = 4) or molecular minimal residual disease (n = 1). All other patients received aDLT in an adjuvant prophylactic setting with full donor chimerism and without the evidence of minimal residual disease. Seven patients received one, 15 patients received two, and 24 patients received three transfusions in escalating doses, containing a median of 1 × 10 6 , 5 × 10 6 and 1 × 10 7 CD3+ lymphocytes per kg patient BW at aDLT 1, 2 and 3, respectively. The median time from transplantation to first aDLT was 160 days (range 71-303). Reasons for giving o3 transfusions were GvHD, infection, relapse Abbreviations: CT = chemotherapy; RAEB = refractory anemia with excess of blasts; RIC = reduced intensity conditioning; sAML = secondary AML; tAML = therapy-associated AML.
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Disease control, survival and complications Median follow-up after alloSCT among surviving aDLT recipients was 7.2 years (range 2.3-11.4) and among controls was 9.4 years (range 2.4-11.1). At the time of analysis, 31/46 aDLT recipients were alive and in CR at a median of 5.7 years post first aDLT. The Kaplan-Meier estimates for OS from transplantation among aDLT recipients at 4 and 7 years were 78% and 67%, as compared with 34% and 31% in the control group (P o 0.001). Six patients from the control group were excluded from the landmark analysis because of relapse before day +160 (median day of first aDLT) after transplantation. Estimated median LFS from the landmark was 599 days in the control group and has not been reached in the aDLT group. The LFS from the landmark is depicted in Figure 1 showing a 6-year LFS of 68% after first aDLT as compared with 38% in the control group (P = 0.011). So far, 10 patients (22%) have relapsed despite aDLT, as compared with 53% in the control group (P = 0.004). The characteristics of patients experiencing relapse despite aDLT are summarized in Table 3 . Eight of ten relapsed patients were transplanted from related donors, compared with 14 of 36 patients, who have not relapsed after aDLT. Thus, patients transplanted from related donors had a significantly higher risk of relapse after aDLT, compared with patients with unrelated donors (P = 0.017). Notably, none of the relapsed patients had developed GvHD after DLT. All relapsed patients in both groups finally died despite further adoptive immunotherapy, including second transplants. Median OS after relapse was 13.5 months (range 1-61) among aDLT recipients as compared with 3.5 months (range 1-24) in the control group. Therefore, differences in OS between the two groups are even more pronounced (data not shown). Three of the relapsed patients had declining chimerism before aDLT and could not be converted. By contrast, one patient with early low chimerism (20% in bone marrow at day+30) could be rescued by early aDLT. Likewise the patient with core binding factor ß -myosin heavy chain fusion gene (CBFßMYH) minimal residual disease became negative by nested PCR after aDLT. Following aDLT, 12 patients (35.3%) developed aGvHD or cGvHD, which was the major complication (Table 4) . Grade II/III aGvHD occurred in four, and cGvHD in eight patients (limited disease, n = 5; extensive disease, n = 3). The risk of developing GvHD after aDLT was higher in the 21 patients with a history of aGvHD after transplantation (430%) as compared with those without aGvHD (10%). There were no cases of marrow aplasia/ cytopenias after aDLT. Non-relapse mortality of aDLT was 11% with patients dying from severe cGvHD (bronchiolitis obliterans; n = 1), infection (n = 2; caused by hepatitis B reactivation and atypical pneumonia, respectively) and secondary solid tumor (n = 2; one bronchial carcinoma at 4 years and one cancer of unknown primary at 9 years after first aDLT.
DISCUSSION
It is widely accepted that DLT provide a strong GVL effect. However, its use in the treatment of AML has limitations. Because of its slow onset of function, DLT is less efficacious in rapidly progressive diseases with high leukemic load, such as overt hematological relapse of AML, only resulting in small numbers of durable remissions. 2, 10, 13 The role of donor lymphocytes in the therapy of AML might be more promising when used as prophylactic or preemptive strategy to control residual disease and to provide immunological surveillance.
Prophylactic, truly adjuvant DLTs have been reported only in very few patients with a mixture of hematological malignancies. 14, 15 Our data represent, by far, the largest study on the use of aDLT in high-risk AML after RIC with long-term follow-up and incorporate a well-matched control group. Abbreviation: aDLT = adjuvant transfusion of donor lymphocyte. Figure 1 . Landmark analysis of leukemia-free survival. Probability of leukemia-free survival after first aDLT for aDLT patients (solid line) and leukemia-free survival after the landmark (median time to first aDLT of aDLT patients) for control patients (dotted line). Log-rank test P = 0.011.
Our results, representing an extension of the previously reported 12 patients from a prospective study with identical inclusion criteria, 9 are encouraging with a 4-and 7-year OS after transplant of 78% and 67%, as compared with 34% and 31% in the control group. After a median of 7.2 years after transplantation, we report a significantly lower relapse rate and even in relapsed patients a prolonged survival after relapse for the aDLT group as compared with the control group.
Of note, we observed a significantly higher risk of relapse in aDLT recipients transplanted from sibling donors as compared with patients grafted from unrelated donors. This might suggest either an enhanced GVL effect of unrelated aDLTs or, as relapses occurred rather shortly after the last aDLT, a suboptimal timing of aDLTs in the related setting.
GvHD was the main toxicity, occurring in about 1/3 of aDLT recipients. With 52% of patients being transplanted from unrelated donors, this rate of GvHD was lower than expected. Furthermore, GvHD-associated mortality was low, as only one patient died of DLT-induced cGvHD of lungs (bronchiolitis obliterans).
The low incidence and severity of aDLT-induced GvHD can be explained by using an escalating dosing regimen and allowing time after alloSCT for tolerance establishment (first dose at day 4120 after transplantation). The importance of the T-cell dose is well established in CML patients. 16, 17 The necessity of allowing a sufficient time interval for tolerance induction prior to the first aDLT has been demonstrated in canine littermate models. 4 The interval of 4120 days after alloSCT seems to be suitable to reduce the incidence of severe GvHD, while preventing early relapses. The study of de Lima et al., 14 applying prophylactic DLTs at day +30, reported an incidence of GvHD of 50%, indicating that a short interval from transplantation to DLT may incorporate a high GvHD risk. Furthermore, the optimal interval between the courses of aDLTs remains to be established as this interval varies widely in published studies. 10, 14, 17, 18 Alternatively, to the truly adjuvant application, DLT may also be administered in a preemptive setting guided by mixed chimerism or the detection of minimal residual disease. 10, 15, 19, 20 In our study, five patients are included who have been treated with DLT in a preemptive setting. One patient with low chimerism at day +30 reached full donor chimerism after early DLT infusion, whereas four patients with declining donor chimerism could not be rescued and relapsed despite of DLT. Hence, our limited experience with high-risk AML patients differs from studies showing better success in chimerism-guided preemptive DLT therapy. 10, 15, 21, 22 Interventions based on minimal residual disease detection are promising. Yan et al. 23 recently published a study on a large cohort of standard-risk AML patients showing improved outcome of minimal residual disease-positive patients after treatment with modified donor lymphocytes. In our study, one patient with detectable minimal residual disease became negative after DLT and remained in complete hematological and molecular remission. However, up to now, it remains to be determined whether minimal residual disease-guided intervention would also be an option in high-risk AML patients with detectable genetic abnormalities.
Strategies aiming to separate GvHD from the GVL effect with manipulated donor lymphocytes (for example, leukemia-specific T cells, HLA-minor antigen-specific T cells, suicide gene transformed donor lymphocytes and so on) 24 are cumbersome and costly, and until now are the subject of research.
The major limitations of our study are the still relatively small patient numbers, the retrospective character of the analysis and the lack of randomization, partially compensated by including a well-matched control group. To avoid bias, we performed landmark analyses, thereby excluding control group patients relapsing before day 160 (median time from transplantation to first aDLT in aDLT recipients). Nevertheless, the selected control cohort still harbors some limitations. Notably, patients in the control group received more frequently bone marrow as stem cell graft, which has been postulated to have an inferior GVL effect in Abbreviations: bro = brother; cGvHD = chronic GvHD; d = days; DLT = donor lymphocyte transfusion; mud = matched unrelated donor; mmud = mismatched unrelated donor; NA = not applicable; PIF = primary induction failure; RAEB = refractory anemia with excess of blasts; Rel = relapse; sAML = secondary AML; sis = sister; ΣCD3 = cumulative CD3 positive T-cell dose/kg body weight of the recipient; Δ last DLT-relapse = time period from last aDLT to relapse. Abbreviation: aDLT = adjuvant transfusion of donor lymphocyte.
Adjuvant donor lymphocyte transfusion in AML Z Jedlickova et al high-risk patients, as compared with PBSC grafts. 25 However, this seems to be counterbalanced to some extent by more standard myeloablative conditioning and a less frequent use of in vivo T-cell depletion in this very group, both being assumed to be associated with a higher antileukemic activity. 26, 27 In conclusion, this study demonstrates that adjuvant, unmanipulated DLT from related and unrelated donors are safe and highly effective in preventing post-transplantation relapse in highrisk AML. Eligible patients treated with aDLT have an excellent chance for long-term survival in spite of high-risk disease.
